Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
November 28, 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
November 14, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder
June 05, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in the ASCEND study Trials in two mood disorders now underway with AXS-05 NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a...
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
April 09, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
December 21, 2017 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
September 05, 2017 08:00 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
February 16, 2017 07:02 ET
|
Neuralstem, Inc.
- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development...
Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.
December 12, 2016 07:38 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder
May 26, 2016 08:15 ET
|
Minerva Neurosciences, Inc
Reduction in depressive symptoms demonstrated Good tolerability and safety profile observed Positive effect on sleep architecture shown Differentiated mechanism of action WALTHAM,...
Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia
May 26, 2016 08:00 ET
|
Minerva Neurosciences, Inc
Statistically significant improvement in PANSS negative symptoms and total PANSS scores observed MIN-101 shown to be statistically superior on key secondary endpoints Effect of MIN-101...